Skip to content
Back to meeting Original
Targeted Oncology· @TargetedOnc · X·· 2 days agoScore45

olomorasib

Body

New at #ESMO26: @mvnegrao @UTMDAnderson discusses the hepatic safety of first-line olomorasib plus pembrolizumab and chemo in KRAS G12C-mutant non–small cell lung cancer.

Watch: https://www.targetedonc.com/view/olomorasib-combination-manageable-liver-toxicity-kras-g12c-mutant-nsclc

69 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
2683Pmatched by NSCLC, metastatic

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

Source: Targeted Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.